Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New therapeutic possibilities for uncontrolled bleeding].

Borbála Mikos1, Klára Kiss, Aranka Bolyos

  • 1Borsod-Abaúj-Zemplén megyei Kórház és Egyetemi Oktató Kórház, Gyermekegészségügyi Központ, Miskolc.

Orvosi Hetilap
|March 19, 2004
PubMed
Summary

Recombinant factor VIIa (rFVIIa) effectively controls bleeding at injury sites without widespread clotting. This study reviews its use in pediatric patients with various bleeding types.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Results in our symptomatic and presymptomatic SMA patients treated with disease-modifying therapy].

Ideggyogyaszati szemle·2025
Same author

[Results of neonatal screening for spinal muscular atrophy in Hungary in 2023].

Orvosi hetilap·2024
Same author

SARS-CoV-2-associated inflammatory multisystem disease in a 15-year-old boy

Orvosi hetilap·2021
Same author

Our initial experiences with intravenous gene therapy for spinal muscular atrophy in children

Orvosi hetilap·2020
Same author

Factors influencing antimicrobial resistance and outcome of Gram-negative bloodstream infections in children.

Infection·2015
Same author

Evaluation of an open access software for calculating glucose variability parameters of a continuous glucose monitoring system applied at pediatric intensive care unit.

Biomedical engineering online·2015

Area of Science:

  • Hematology
  • Pharmacology

Background:

  • Recombinant factor VIIa (rFVIIa) is a procoagulant agent.
  • It is known to enhance local hemostasis without systemic coagulation activation.
  • rFVIIa supports thrombin generation in cases of impaired coagulation and thrombocytopenia.

Observation:

  • This paper presents three pediatric cases where rFVIIa was administered.
  • The patients experienced uncontrolled bleeding, including traumatic, surgical, nontraumatic, thrombocytopenic, and coagulopathic types.
  • rFVIIa was used to mitigate this bleeding.

Findings:

  • rFVIIa demonstrated efficacy in managing diverse bleeding conditions in pediatric patients.
  • The treatment was targeted to the site of injury, minimizing systemic procoagulant effects.

Related Experiment Videos

  • Successful application in traumatic, surgical, and thrombocytopenic bleeding scenarios was observed.

    • Implications:

    • The findings support the clinical utility of rFVIIa in pediatric hemostasis management.
    • Understanding the complex mechanism of rFVIIa is crucial for optimizing its therapeutic application.
    • Further research into rFVIIa's mechanism could refine treatment protocols for bleeding disorders.